Gishlaine Alfonso Mendez, MD
Neurology · San Juan, PRNPI 1053374975
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,135 of the $52,831 with a category attached, or 76.0%. AstraZeneca accounts for 84.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2024 at $19,819 and has fallen 93.3% since, to $1,323 in 2025. Among neurology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $163.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$45K
- Biogen$2K
- EMD Serono, Inc.$1K
- Novartis$855
- AbbVie$503
- E.r. Squibb & Sons, L.L.C.$499
- plus $3K from 23 others
Across 3 payments — averaging $4498.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$13K
What the payments were for
- Speaking & faculty fees$40,13576%
- Travel & lodging$2,8225%
- Food & beverage$9,74918%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 53 | $44,716 |
| Biogen | 85 | $1,541 |
| EMD Serono, Inc. | 20 | $1,350 |
| Novartis | 36 | $855 |
| AbbVie(2 entities) | 15 | $503 |
| E.r. Squibb & Sons, L.L.C. | 16 | $499 |
| Genentech USA, Inc. | 19 | $414 |
| Teva Pharmaceuticals USA, Inc. | 11 | $413 |
| UCB, Inc. | 4 | $315 |
| Amgen(2 entities) | 10 | $300 |
| Sanofi | 8 | $258 |
| Banner Life Sciences, LLC | 6 | $218 |
| Johnson & Johnson(2 entities) | 2 | $166 |
| TG Therapeutics, Inc. | 2 | $147 |
| Biohaven Pharmaceuticals, Inc. | 7 | $147 |
| Eli Lilly Export S.A. Puerto Rico Branch | 9 | $130 |
| Eisai Inc. | 1 | $118 |
| Argenx US, Inc. | 1 | $118 |
| Akcea Therapeutics, Inc. | 1 | $114 |
| Lundbeck LLC | 1 | $113 |
| Lilly USA, LLC | 3 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $82 |
| PBG Puerto Rico LLC | 4 | $80 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $20 |
| CSL Behring | 1 | $20 |
| Pfizer Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,831 in reported general payments places this provider in the 95th percentile of 129 neurology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 72 | $1,016,894 |
| Emgality PenGalcanezumab-Gnlm | 45 | $34,757 |
| Dalfampridine ErDalfampridine | 34 | $34,146 |
| UbrelvyUbrogepant | 19 | $18,441 |
| Pyridostigmine Bromide | 190 | $14,296 |
| QuliptaAtogepant | 11 | $12,159 |
| Galantamine ErGalantamine Hbr | 107 | $11,359 |
| Riluzole | 73 | $5,526 |
| AriceptDonepezil Hcl | 12 | $5,504 |
| Rivastigmine | 22 | $4,706 |
| Pramipexole ErPramipexole Di-Hcl | 17 | $4,291 |
| Memantine Hcl | 106 | $2,811 |
| Mycophenolate Mofetil | 36 | $2,384 |
| Carbamazepine ErCarbamazepine | 22 | $2,014 |
| Oxcarbazepine | 27 | $1,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $503 | $30,60130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 neurology providers in Puerto Rico.
Other neurology in San Juan
- Franchesca Fiorito-TorresSan Juan$453K
- Mari GarciaSan Juan$138K
- Cristina Cabret-AymatSan Juan$108K
- Carlos Luciano-RomanSan Juan$21K
- Maria Garcia-AyalaSan Juan$10K
- Marisol Mubarak PerdomoSan Juan$10K
- Enrique Rodriguez OlaverriSan Juan$8K
- Ricardo Alvarado MelendezSan Juan$6K
- Hector Miranda DelgadoSan Juan$6K
- Ludemar Roman AcostaSan Juan$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.